Interestingly, in a recent study using resistant colon cancer stem-like cells and mouse models, combination therapy of regorafenib with two antagonists of IGF-1-R, namely aspirin and the selective dual insulin receptor and IGF-1R kinase inhibitor linsitinib (OSI-906), abrogated tumor resistance to regorafenib and restored the drug’s ability to induce apoptosis in colon cancer stem-like cells and disease activity index (51). The gene discussed is INSR; the disease is colonic neoplasm.